Wolfe Research raised the firm's price target on Leslie's to $3 from $2 and keeps an Outperform rating on the shares. Leslie's Q2 results were relatively strong, and further cost-cutting benefits should continue to benefit the business over the next 12 months, the analyst tells investors in a research note.
